{'fraction_non_alphanumeric': 0.0260950605778192, 'fraction_numerical': 0.001863932898415657, 'mean_word_length': 5.884615384615385, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Periostin levels in chronic obstructive pulmonary disease (COPD)

Background: Periostin is an extracellular matrix protein that reflects airway epithelial injury. In asthma, periostin is considered to be useful as a biomarker of type 2 inflammation. In addition, it has been reported that periostin associates with respiratory diseases such as idiopathic pulmonary fibrosis. However, it is unknown that the relationship between periostin and other biomarkers in chronic obstructive pulmonary disease (COPD). Objective: We investigated the relationship between serum periostin levels and other biomarkers including serum markers and pulmonary function. Methods: Ninety-three COPD patients were enrolled, and we reviewed associations among serum periostin, other serum biomarkers and clinical features. Results: Fractional exhaled nitric oxide (FeNO), IgE, and age showed correlations with serum periostin levels respectively, whereas blood eosinophils and stages of COPD showed no correlations. Conclusion: Periostin may be a useful biomarker of type 2 inflammation in COPD.